MediciNova, Inc. 2013 Form 10-K Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on small-molecule therapeutics for serious diseases with unmet medical needs, primarily targeting the U.S. market. This Form 10-K covers the fiscal year ended December 31, 2013; quarterly data include the fourth quarter ended December 31, 2013.
The principal development programs were MN-166 (ibudilast) for neurological disorders and addiction, MN-221 (bedoradrine) for acute asthma exacerbations, MN-001 (tipelukast) for NASH, and MN-029 (denibulin) for solid tumors. No product candidate had received regulatory approval or generated product-sales revenue.
Key financial metrics
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Revenue | $6.003 million | $0.803 million | Increased $5.200 million |
| Operating expenses | $10.024 million | $11.748 million | Decreased $1.724 million |
| Operating loss | $4.021 million | $10.945 million | Improved $6.925 million |
| Net loss | $4.029 million | $10.961 million | Improved $6.933 million |
| Net loss per share | $0.19 | $0.66 | Improved |
| Net cash used in operations | $10.646 million | $11.864 million | Improved $1.218 million |
| Cash and cash equivalents at year-end | $6.700 million | $4.011 million | Increased $2.690 million |
| Working capital | $13.922 million | $3.384 million | Increased $10.538 million |
| Total assets | $29.546 million | $19.568 million | Increased $9.978 million |
| Stockholders’ equity | $25.426 million | $14.880 million | Increased $10.546 million |
Revenue consisted primarily of a $6.0 million Genzyme development milestone recognized in December 2013, with the related receivable collected in January 2014, and approximately $3,000 of research and development service revenue. The milestone had no related 2013 expense.
Research, development and patent expense declined to $3.366 million from $5.013 million, principally because MN-221 trial spending fell by $3.4 million after completion of the MN-221-CL-007 trial. This was partly offset by a $1.3 million increase in MN-166 trial spending. General and administrative expense was substantially unchanged at $6.658 million versus $6.735 million.
MediciNova had no outstanding debt and no interest expense at December 31, 2013. Total liabilities were $4.120 million, including $1.694 million of long-term deferred revenue and a $1.956 million deferred tax liability. Accumulated deficit was $301.4 million, including $51.6 million of non-cash stock-based compensation charges accumulated since inception.
Fourth-quarter results
| Metric | Q4 2013 | Q4 2012 |
|---|---|---|
| Revenue | $6.000 million | $0.034 million |
| Operating expenses | $2.573 million | $2.455 million |
| Net income (loss) | $3.413 million | $(2.434) million |
| Diluted earnings (loss) per share | $0.14 | $(0.14) |
The fourth-quarter profit was driven by the one-time $6.0 million Genzyme milestone and does not represent recurring operating profitability.
Material changes and operating developments
- MN-166 development expanded in progressive multiple sclerosis, methamphetamine dependence, opioid withdrawal, alcohol dependence and marijuana dependence. SPRINT-MS enrollment began in late 2013 for a planned 240-patient Phase 2 trial.
- The FDA granted Fast Track designation for MN-166 for methamphetamine dependence in February 2013.
- MN-221 did not statistically meet its primary FEV1 endpoint in the 175-patient Phase 2b trial, although certain FEV1 area-under-the-curve measures, symptoms and hospital admissions showed favorable results. Further development is dependent on obtaining a financial partner.
- MediciNova began preparing a U.S. clinical trial of MN-001 for NASH and planned additional MN-166 addiction studies.
- MN-029 received a U.S. patent Notice of Allowance covering denibulin di-hydrochloride, with expected patent expiration no earlier than July 2032.
- The company raised approximately $13.4 million net through common-stock and warrant issuances in 2013. It also maintained a $10 million at-the-market equity facility and sold additional shares after year-end.
- Common shares issued increased to 22.5 million at year-end from 17.4 million, excluding potential dilution from preferred stock, options and warrants.
Liquidity, outlook and risks
Management expected approximately $13.8 million of cash as of March 31, 2014 and projected approximately $4.3 million of spending from April 1 through December 31, 2014. The filing stated that working capital was expected to fund operations through June 30, 2015, but emphasized that additional financing would likely be required for significant clinical development.
MediciNova expected research and development expense to decline in 2014 because of reduced employee costs and increased reliance on externally funded or investigator-sponsored trials. Management stated that it expected substantial losses to continue for the foreseeable future and did not expect product-sales revenue for several years, if ever.
Key risks include the need for additional capital, dilution from equity financings, failure or delay of clinical trials, regulatory non-approval, safety or efficacy concerns, dependence on third-party manufacturers and clinical research organizations, reliance on strategic partners, intellectual-property limitations, competition, product-liability exposure and potential inability to maintain exchange-listing requirements.
Future potential license milestone obligations totaled approximately $10.0 million for products currently in development and $84.1 million for other products, although timing was uncertain. Contractual obligations included approximately $3.125 million of operating lease and remaining research-and-development commitments.
The company reported no material legal proceedings. Management and Ernst & Young concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2013, and the audit opinion was unqualified.
Important facts for investors to verify
- Verify that 2013 revenue and Q4 profit were substantially driven by the non-recurring $6.0 million Genzyme milestone rather than product sales.
- Assess cash runway using the $10.646 million 2013 operating cash burn, projected 2014 spending, post-year-end equity proceeds and expected clinical-trial costs.
- Review the status, enrollment and financing of the MN-166 programs, particularly SPRINT-MS and addiction studies.
- Evaluate the implications of MN-221’s missed primary endpoint and the FDA’s requirement for a clinical endpoint such as reduced hospitalizations in any pivotal study.
- Analyze potential dilution from 3.761 million warrants, 3.217 million options and 2.2 million shares issuable upon conversion of preferred stock.
- Review license milestones, royalties, patent expiration dates and the company’s limited composition-of-matter protection for MN-166 and MN-001.
- Confirm subsequent events, including receipt of the $6.0 million Genzyme payment and approximately $3.0 million of net post-year-end ATM equity proceeds.